After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?

Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives. Unfortunately, intepirdine failed to outperform a placebo in its study, a result that casts doubt over Axovant Sciences' future.

In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass and contributor Todd Campbell unpack this news and offer up their take on why Axovant shares are still risky, even after the 70% drop the took following the disappointing clinical trial news.

A full transcript follows the video.

Source: Fool.com